Clinical Cancer Research, Vol 3, Issue 8 1339-1346, Copyright © 1997 by American Association for Cancer Research

ARTICLES

Suppression of P-glycoprotein expression and multidrug resistance by DNA cross-linking agents

MA Ihnat, JP Lariviere, AJ Warren, N La Ronde, JR Blaxall, KM Pierre, BW Turpie and JW Hamilton
Department of Pharmacology and Toxicology, Dartmouth Medical School, Hanover, New Hampshire 03755-3835, USA.

Overexpression of the trans-membrane drug efflux pump P-glycoprotein is one of the major mechanisms by which cancer cells develop multidrug resistance. We demonstrated previously that noncytotoxic doses of various genotoxic chemicals, particularly DNA cross-linking agents, preferentially altered expression of inducible genes. These effects occurred principally at the transcriptional level and were closely correlated temporally with DNA damage. Because the mdr1 gene coding for P-glycoprotein has been reported to be highly inducible, we were interested in the effects of genotoxic cancer chemotherapy agents on its expression. We report that the DNA cross-linking agent mitomycin C significantly suppressed mRNA and protein expression of P-glycoprotein and decreased the rate of drug efflux. Mitomycin C pretreatment also significantly increased the sensitivity of cancer cells to subsequent killing by the P-glycoprotein substrate doxorubicin, decreasing the ED50 by 5- to 10-fold. Suppression of P-glycoprotein expression was also observed with subtoxic doses of the DNA cross-linking agents cisplatin, BMS181174, and chromium(VI). These effects occurred in both human and rodent cell lines; in cell lines derived from colon, breast, leukemia, neuroblastoma, and hepatoma tumors; and under both monolayer and "spheroid" culture conditions. These results suggest the basis for novel clinical cancer chemotherapy regimens aimed at drug-resistant tumors, in which a sub-chemotherapeutic dose of a DNA cross-linking agent is used to modulate the multidrug resistance phenotype prior to treatment with a second cytotoxic agent.

This article has been cited by other articles:

				A. E.M. Vickers, K. Rose, R. Fisher, M. Saulnier, P. Sahota, and P. Bentley Kidney Slices of Human and Rat to Characterize Cisplatin-Induced Injury on Cellular Pathways and Morphology Toxicol Pathol, August 1, 2004; 32(5): 577 - 590. [Abstract] [PDF]

				Y.-D. Wei, K. Tepperman, M.-y. Huang, M. A. Sartor, and A. Puga Chromium Inhibits Transcription from Polycyclic Aromatic Hydrocarbon-inducible Promoters by Blocking the Release of Histone Deacetylase and Preventing the Binding of p300 to Chromatin J. Biol. Chem., February 6, 2004; 279(6): 4110 - 4119. [Abstract] [Full Text] [PDF]

				R. Maitra, C. M. Shaw, B. A. Stanton, and J. W. Hamilton Increased functional cell surface expression of CFTR and {Delta}F508-CFTR by the anthracycline doxorubicin Am J Physiol Cell Physiol, May 1, 2001; 280(5): C1031 - C1037. [Abstract] [Full Text] [PDF]

				A. J. Warren, D. J. Mustra, and J. W. Hamilton Detection of Mitomycin C-DNA Adducts in Human Breast Cancer Cells Grown in Culture, as Xenografted Tumors in Nude Mice, and in Biopsies of Human Breast Cancer Patient Tumors as Determined by 32P-Postlabeling Clin. Cancer Res., April 1, 2001; 7(4): 1033 - 1042. [Abstract] [Full Text]

				U. Benbow, R. Maitra, J. W. Hamilton, and C. E. Brinckerhoff Selective Modulation of Collagenase 1 Gene Expression by the Chemotherapeutic Agent Doxorubicin Clin. Cancer Res., January 1, 1999; 5(1): 203 - 208. [Abstract] [Full Text] [PDF]